CU20210006A7 - Derivados de fenil-n-quinolina y proceso para su preparación - Google Patents

Derivados de fenil-n-quinolina y proceso para su preparación

Info

Publication number
CU20210006A7
CU20210006A7 CU2021000006A CU20210006A CU20210006A7 CU 20210006 A7 CU20210006 A7 CU 20210006A7 CU 2021000006 A CU2021000006 A CU 2021000006A CU 20210006 A CU20210006 A CU 20210006A CU 20210006 A7 CU20210006 A7 CU 20210006A7
Authority
CU
Cuba
Prior art keywords
group
cycloalkyl
phenyl
orc
formula
Prior art date
Application number
CU2021000006A
Other languages
English (en)
Other versions
CU24674B1 (es
Inventor
Cécile Apolit
Florence Mahuteau-Betzer
Romain Najman
Julien Santo
Didier Scherrer
Jamal Tazi
Original Assignee
Centre Nat Rech Scient
Inst Curie
Univ Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Inst Curie, Univ Montpellier filed Critical Centre Nat Rech Scient
Publication of CU20210006A7 publication Critical patent/CU20210006A7/es
Publication of CU24674B1 publication Critical patent/CU24674B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>La presente invención se refiere a un compuesto de fórmula (I) o cualquiera de sus sales farmacéuticamente aceptables para usarse en el tratamiento y/o prevención de una infección por virus ARN, y en particular una infección por virus ARN del grupo IV o V de la clasificación de Baltimore.</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>en donde R3 representa un átomo de cloro o un átomo de hidrógeno, R representa un grupo alquilo (C1-C4), un grupo cicloalquilo (C3-C6), un átomo de halógeno, un grupo alcoxi (C1-C5), un grupo -SO2-NRaRb, un grupo -SO3H, un grupo -OH, un grupo -O-SO2-ORc o un grupo -OP (= O) - (ORc) (ORd), R1 representa (i) un grupo CF3, (ii) un grupo alquilo (C1-C10), (iii) un grupo cicloalquilo (C3-C6) o un grupo heterocicloalquilo (C3-C6) o (iv) un grupo fenilo o un grupo naftilo, y R2 representa un átomo de hidrógeno, un grupo alquilo (C1-C10), un cicloalquilo (C3-C6) o un grupo heterocicloalquilo (C3-C6). La presente invención se refiere además a nuevos compuestos, a composiciones farmacéuticas que los contienen y al proceso de síntesis para manufacturarlos.</p>
CU2021000006A 2018-07-09 2019-07-09 Derivados de fenil-n-quinolina y proceso para su preparación CU24674B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305910.4A EP3594206A1 (en) 2018-07-09 2018-07-09 Phenyl-n-quinoline derivatives for treating a rna virus infection
PCT/EP2019/068459 WO2020011810A1 (en) 2018-07-09 2019-07-09 Phenyl-n-quinoline derivatives for treating a rna virus infection

Publications (2)

Publication Number Publication Date
CU20210006A7 true CU20210006A7 (es) 2021-08-06
CU24674B1 CU24674B1 (es) 2023-08-08

Family

ID=63035966

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000006A CU24674B1 (es) 2018-07-09 2019-07-09 Derivados de fenil-n-quinolina y proceso para su preparación

Country Status (11)

Country Link
US (1) US20210309611A1 (es)
EP (2) EP3594206A1 (es)
JP (2) JP2021524481A (es)
KR (1) KR20210052432A (es)
CN (1) CN112566899B (es)
AU (1) AU2019300100A1 (es)
BR (1) BR112021000331A2 (es)
CA (1) CA3103867A1 (es)
CU (1) CU24674B1 (es)
MX (1) MX2021000089A (es)
WO (1) WO2020011810A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4121053A1 (en) 2020-03-20 2023-01-25 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
EP3884946A1 (en) 2020-03-25 2021-09-29 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
EP3881844A1 (en) 2020-03-20 2021-09-22 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2465502A1 (en) * 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
CN105530938B (zh) * 2013-07-05 2019-10-22 Abivax公司 用于治疗由逆转录病毒引起的疾病的化合物
EP3058940A1 (en) * 2015-02-23 2016-08-24 Abivax Quinoline derivatives for use in the treatment or prevention of viral infection
EP3059591A1 (en) * 2015-02-23 2016-08-24 Abivax Methods for screening compounds for treating or preventing a viral infection or a virus-related condition

Also Published As

Publication number Publication date
JP2024053563A (ja) 2024-04-15
JP2021524481A (ja) 2021-09-13
CN112566899B (zh) 2024-01-30
KR20210052432A (ko) 2021-05-10
MX2021000089A (es) 2021-03-25
EP3820852A1 (en) 2021-05-19
WO2020011810A1 (en) 2020-01-16
CA3103867A1 (en) 2020-01-16
BR112021000331A2 (pt) 2021-04-06
CN112566899A (zh) 2021-03-26
CU24674B1 (es) 2023-08-08
US20210309611A1 (en) 2021-10-07
EP3594206A1 (en) 2020-01-15
AU2019300100A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
CU20210006A7 (es) Derivados de fenil-n-quinolina y proceso para su preparación
PE20200008A1 (es) Isoquinolinas como inhibidores de hpk1
UY38297A (es) Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos
PE20180232A1 (es) Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
NI201000150A (es) Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización.
AR125425A1 (es) Inhibidores de proteina tirosina fosfatasa y sus metodos de uso
AR058077A1 (es) Derivados de acidos fenoxiaceticos
AR036875A1 (es) Acidos hidroxamicos ciclicos como inhibidores de las metaloproteinasas de matriz y/o de la enzima de conversion del factor de necrosis de tumor alfa
AR068055A1 (es) Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol su procedimiento de preparacion su aplicacion como medicamentos composiciones farmaceuticas y su utilizacion principalmente como inhibidores de met
AR050963A1 (es) Derivados bis-azaindolicos, su utilizacion farmaceutica como inhibidores de cinasas y su uso en la fabricacion de medicamentos para el tratamiento de los canceres.
AR082889A1 (es) Compuestos y composiciones para la inhibicion de nampt
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
AR115007A1 (es) Derivados de triazolona o sales de los mismos y composiciones farmacéuticas que comprenden los mismos
CL2021001461A1 (es) Moduladores de trex1
AR103742A1 (es) Derivados de trifluorometilpropanamida
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
HN2011003482A (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)
UY37941A (es) Derivados de bencimidazol y sus usos
CU20210038A7 (es) Compuestos derivados sustituidos de 6,7-dihidro- 4h-pirazolo pirazinindol-2&#39; carboxamidas activas contra el virus de la hepatitis b (vhb)
CU20210005A7 (es) Derivados de fenil/piridil-n-fenil/piridilo útiles para el tratamiento de una infección por virus de ácido ribonucleico (arn)
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
AR053862A1 (es) Sales de monolisina de compuestos de triazol
CO2021004873A2 (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa